Quality Pharma Products Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 16-11-2024
- Paid Up Capital ₹ 2.12 M
as on 16-11-2024
- Company Age 27 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.00 Cr
as on 16-11-2024
- Satisfied Charges ₹ 6.90 Cr
as on 16-11-2024
- Revenue 48.47%
(FY 2023)
- Profit -32.62%
(FY 2023)
- Ebitda -115.60%
(FY 2023)
- Net Worth 6.12%
(FY 2023)
- Total Assets -9.83%
(FY 2023)
About Quality Pharma Products
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.12 M.
The company currently has active open charges totaling ₹4.00 Cr. The company has closed loans amounting to ₹6.90 Cr, as per Ministry of Corporate Affairs (MCA) records.
Khushboo Damani and Shyam Damani serve as directors at the Company.
- CIN/LLPIN
U51397AS1997PTC007500
- Company No.
007500
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Oct 1997
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Shillong
Industry
Company Details
- Location
Dibrugarh, Assam, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Quality Pharma Products?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shyam Damani  | Director | 11-Nov-2009 | Current |
| Khushboo Damani | Director | 01-Apr-2015 | Current |
Financial Performance of Quality Pharma Products.
Quality Pharma Products Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 48.47% increase. The company also saw a substantial fall in profitability, with a 32.62% decrease in profit. The company's net worth moved up by a moderate rise of 6.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Quality Pharma Products?
In 2023, Quality Pharma Products had a promoter holding of 76.59% and a public holding of 23.41%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Warkem Properties Pvt LtdActive 29 years 8 monthsKhushboo Damani and Shyam Damani are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 21 Feb 2014 | ₹4.00 Cr | Open |
Others Creation Date: 01 Feb 2017 | ₹2.50 Cr | Satisfied |
State Bank Of India Creation Date: 23 Nov 2004 | ₹4.40 Cr | Satisfied |
How Many Employees Work at Quality Pharma Products?
Quality Pharma Products has a workforce of 28 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Quality Pharma Products, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Quality Pharma Products's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
